Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-reported neuropathy-guided oxaliplatin dose modification in metastatic colorectal cancer
ACTRN12616001536459Phase 2Recruiting
- Sponsor
- Regional Cancer Treatment Service
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in colorectal cancer (CRC), sponsored by Regional Cancer Treatment Service. Primary endpoint: Acceptability of the intervention. Started Mar 2017; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ACTRN12616001536459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616001536459.